Qian Wang

Dr. Qian Wang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2022 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
BMBeilei Ma
Beilei Ma
TWTengkai Wang
Tengkai Wang
JLJuan Li
Juan Li
QWQian Wang
Qian Wang
Background: Angiogenesis is required in many physiological conditions, including bone regeneration, wound healing, and tissue regeneration. Mesenchymal stem cells-derived extracellular matrix (MSCs-ECM) could guide intricate cellular and tissue processes such as homeostasis, healing and regeneration.Methods: The purpose of this study is to explore the effect and mechanism of ECM derived from decellularized Wharton's Jelly-derived mesenchymal stem cells (WJ-MSCs) on endothelial cell viability and angiogenesis. The human umbilical vein endothelial cells (HUVECs) were pretreated with WJ-MSCs ECM for 2d/7d/14d, respectively. After pretreatment, the angiogenesis ability of HUVECs was detected.Results: In this study, we found for the first time that WJ-MSCs ECM could improve the angiogenesis ability of HUVECs with a time-dependent manner in vitro. Mechanically, WJ-MSCs ECM activated the focal adhesion kinase (FAK)/P38 signaling pathway via integrin αVβ3, which further promoted the expression of the cellular (c)-Myc. Further, c-Myc increased histone acetylation levels of the vascular endothelial growth factor (VEGF) promoter by recruiting P300, which ultimately promoting VEGF expression.Conclusions: ECM derived from Wharton’s Jelly-derived mesenchymal stem cells promotes angiogenesis via integrin αVβ3/c-Myc/P300/VEGF.This study is expected to provide a new approach to promote angiogenesis in bone and tissue regeneration.

31 October 2019 in Oncology Reports
Verified
Journal Article
Open access
PDF file
XKXiangnan Kong
Xiangnan Kong
MLMin Li
Min Li
KSKai Shao
Kai Shao
YYYinrong Yang
Yinrong Yang
QWQian Wang
Qian Wang
MCMeijuan Cai
Meijuan Cai
Endometrial cancer (EC) is one of the most common malignant gynecological tumors in women. The main treatments for EC (surgery, chemotherapy and radiation therapy) produce significant side effects. Thus, it is urgent to identify promising therapeutic targets and prognostic markers. CACNA2D3, as a member of the calcium channel regulatory α2δ subunit family, is reported to exert a tumor suppressive effect in numerous cancers. However, the function of CACNA2D3 in EC is not well known. In the present study, CACNA2D3 was lowly expressed in EC tissues and cells. The overexpression of CACNA2D3 via lentiviral particle injection significantly blocked the tumor growth in an in vivo xenograft model. In vitro, the overexpression of CACNA2D3 markedly inhibited cell proliferation and migration, and promoted cell apoptosis and calcium influx. These data revealed that CACNA2D3 functions as a tumor suppressor in EC. It was also revealed that the addition of progesterone (P4) blocked tumor growth in Ishikawa‑injected nude mice. P4 induced the expression of CACNA2D3 in vivo and in vitro, and the silencing of CACNA2D3 affected P4‑inhibited cell proliferation and P4‑induced cell apoptosis and calcium influx. In Ishikawa cells, P4 enhanced the expression of phosphorylated (p)‑p38 MAPK and PTEN, but blocked the levels of p‑PI3K and p‑AKT. The knockdown of CACNA2D3 blocked the function of P4. These data revealed that P4 promoted cell apoptosis via the activation of the CACNA2D3/Ca2+/p38 MAPK pathway, and blocked cell proliferation via suppression of the PI3K/AKT pathway. Collectively, these findings indicated the antitumor role of CACNA2D3 in EC, and revealed the mechanism of P4 inhibition of EC progression, which provided a new target for EC therapy and new evidence for P4 in EC therapy.

1 June 2021 in Toxicology
Verified
Journal Article
Closed access
TWTengkai Wang
Tengkai Wang
FXFen Xu
Fen Xu
LSLijun Song
Lijun Song
JLJuan Li
Juan Li
QWQian Wang
Qian Wang

30 September 2012 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
HDHui-Zhen Du
Hui-Zhen Du
QWQian Wang
Qian Wang
JJJian Ji
Jian Ji
BSBao-Ming Shen
Bao-Ming Shen
SWShao-Chun Wei
Shao-Chun Wei
MHMing Hou
Ming Hou

18 September 2013 in ISRN Endocrinology
Verified
Journal Article
Open access
PDF file
TWTengkai Wang
Tengkai Wang
QWQian Wang
Qian Wang
ZWZhimei Wang
Zhimei Wang
ZXZuomin Xiao
Zuomin Xiao
LLLunqin Liu
Lunqin Liu
Diabetic nephropathy (DN) is a major cause of end-stage kidney disease, and therefore early diagnosis and intervention may help reverse renal damage. One hundred and sixty-eight patients with T2DM and 56 healthy volunteers (control group) were enrolled at Shandong University Qilu Hospital between April 2010 and October 2012. All subjects underwent blood sampling for sera homocysteine (Hcy) and cystatin C (Cys C) assays and a urine microalbumin test. The patients were divided into three groups according to the urine microalbumin excretion rate (UMAER): the simple DM group (SDM group, n=51), the early-stage DN group (EDN group, n=60), and the clinical DN and renal failure group (CDN group, n=57). Correlation analysis was performed to examine the association between sera Hcy and Cys C levels with UMAER. Our findings showed that sera Hcy level, Cys C level, and UMAER increased significantly in the SDM group (P<0.05, P<0.01), the EDN group (P<0.01), and the CDN group (P<0.01) as compared with the control group. These three biochemical markers also increased significantly with DN progression (P<0.01). Correlation analysis showed that sera Hcy and Cys C levels were positively correlated with UMAER (r=0.702, P<0.01; r=0.873, P<0.01). In conclusion, our results showed that sera Hcy and Cys C levels increased consistently with the development and progression of DN as indicated by UMAER. Sera Hcy and Cys C are sensitive biomarkers for the detection of early-stage DN and monitoring its progression.

1 July 2017 in Acta Tropica
Verified
Journal Article
Closed access
GZGuanghui Zhao
Guanghui Zhao
XSXiaojie Song
Xiaojie Song
XKXiangnan Kong
Xiangnan Kong
NZNing Zhang
Ning Zhang
SQShaoling Qu
Shaoling Qu
QWQian Wang
Qian Wang